US 12,467,038 B2
Methods of culturing human pluripotent cells
Benjamin Eithan Reubinoff, Moshav Bar-Giora (IL); and Michal Gropp, Jerusalem (IL)
Assigned to Hadasit Medical Research Services and Development Ltd., Jerusalem (IL)
Appl. No. 17/613,137
Filed by Hadasit Medical Research Services and Development Ltd., Jerusalem (IL)
PCT Filed May 22, 2020, PCT No. PCT/IL2020/050566
§ 371(c)(1), (2) Date Nov. 22, 2021,
PCT Pub. No. WO2020/234888, PCT Pub. Date Nov. 26, 2020.
Claims priority of provisional application 62/851,121, filed on May 22, 2019.
Prior Publication US 2022/0213445 A1, Jul. 7, 2022
Int. Cl. C12N 5/074 (2010.01); C12N 5/073 (2010.01); C12N 5/0735 (2010.01)
CPC C12N 5/0696 (2013.01) [C12N 5/0603 (2013.01); C12N 5/0606 (2013.01); C12N 5/0611 (2013.01); C12N 2500/98 (2013.01); C12N 2501/115 (2013.01); C12N 2501/727 (2013.01); C12N 2506/03 (2013.01); C12N 2533/52 (2013.01)] 8 Claims
 
1. A method of enriching for a population of formative hPSCs which express WNT receptors but do not express nuclear B-catenin, the method comprising culturing non-formative hPSCs on an adherent surface which comprises a coating of a single protein, said single protein being laminin, said culturing being effected in a culture medium comprising fibroblast growth factor 2 (FGF2), thereby enriching for the population of formative hPSCs which express WNT receptors but do not express nuclear B-catenin.